MedTrace Logo

Cancer and Blood Pressure Management, CARISMA Study

NCT04467021 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2026-05-06

No results posted yet for this study

Summary

This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.

Conditions

  • Cardiovascular Disorder
  • Chronic Kidney Disease
  • Metastatic Renal Cell Carcinoma
  • Metastatic Thyroid Gland Medullary Carcinoma
  • Stage IV Renal Cell Cancer AJCC v8
  • Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8

Interventions

OTHER

Best Practice

Receive usual blood pressure management

OTHER

Blood Pressure Measurement

Undergo blood pressure measurement

OTHER

Clinical Management

Undergo intensive systolic BP management

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Bonnie Ky · ECOG-ACRIN Cancer Research Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04467021 on ClinicalTrials.gov